A Phase III Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Idebenone in Patients with Duchenne Muscular Dystrophy (DMD) who completed the SIDEROS study
Phase of Trial: Phase III
Latest Information Update: 17 Oct 2019
Price : $35 *
At a glance
- Drugs Idebenone (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions; Registrational
- Acronyms SIDEROS-E
- Sponsors Santhera Pharmaceuticals
- 17 Apr 2019 Planned End Date changed from 1 Jan 2022 to 1 Jan 2024.
- 17 Apr 2019 Planned primary completion date changed from 1 Dec 2021 to 1 Dec 2023.
- 17 May 2018 New trial record